Publications
Read below the 20 most recent publications from iCAN.
- by Siiri ReinikkaCONCLUSIONS: Here, we have characterized the genomic landscape of endometrial polyps. We show that chromosomal alterations affecting HMGA1 and HMGA2 are a major underlying cause for polyp development. In addition, we present UBE2A as a novel candidate gene for human tumorigenesis. Our results contribute to a better understanding of endometrial polyp development and pave the […]
- by Rui HanCONCLUSIONS: LOY/EDY can be detected in OPMD and promotes malignant progression by altering oncogenic signaling and epithelial cell interactions. LOY/EDY may serve as both a diagnostic biomarker and a therapeutic target, improving clinical management and patient outcomes.
- by Mari VehviläinenCONCLUSION: The present study suggests that OLL is associated with HT. The association between OLP and HT was not statistically significant. Allergies are associated with OLP.
- by Sakari MäntyselkäSkeletal muscle is the main consumer of glucose after a mixed meal, and resistance exercise further increases muscle glucose uptake. Emerging evidence suggests that glucose uptake in muscles is not only stored as glycogen or used as a fuel but can also be incorporated into other biomass during growth. We aimed to study the utilization […]
- by Yue ZhangTherapeutic toxicity, which can be life-threatening, presents a major challenge in treating patients with acute myeloid leukemia (AML). Medical digital twins, which are virtual representations of patient disease, have the potential to forecast disease progression and simulate potential treatments. Using neutrophil counts and blast percentages, we developed mechanistic models to predict toxicity (neutropenia) in AML […]
- by Marta Pineda-MoncusíBACKGROUND: Drug shortages can negatively impact patient care. We aimed to estimate the incidence and prevalence of use of medicines with shortages announced by the European Medicines Agency between January, 2013, and September, 2023, and to characterise the users of these drugs.
- by Joseph SaadDespite promising anti-leukemic activity of MCL-1 inhibitors in preclinical studies of acute myeloid leukemia (AML), clinical progress has been hindered by limited knowledge of target patient subgroups. To stratify patients for MCL-1 inhibitor treatment, we evaluated the sensitivity of 42 primary AML samples to MCL-1 inhibitor MIK665 (S64315) and analyzed their molecular profiles. We observed […]
- by Debora M MeijerCentral conventional chondrosarcoma, a malignant cartilage-producing bone tumor, is the second most common bone sarcoma. Chondrosarcomas are histologically graded, which is so far the best predictor of survival. Early mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes are frequent, leading to the production of the oncometabolite D-2-hydroxyglutarate, which affects DNA methylation, resulting in a […]
- by Aliisa AuvinenCONCLUSIONS: Our study adds to the evidence that ARB use might have a beneficial impact on survival among GC patients.
- by Zivile GiedraityteCONCLUSIONS: IL-17C appears to play a protective role in some OSCC cells. While this study indicates the potential of using IL-17C as a therapeutic candidate for OSCC patients, its relatively mild and selective effect suggests it may be more effective as part of a combination therapy.
- by Mikko PurhonenTreatment-free remission (TFR) has become a therapeutic objective for selected chronic-phase chronic myeloid leukemia (CP CML). However, no standardized biomarker is yet in clinical use. In this multi-center study, we explored the potential of bone marrow (BM) cytomorphology given its global accessibility and integral role in clinical diagnostics. We included diagnostic BM aspirate samples of […]
- by Piia PeltoniemiCONCLUSION: A single dose of dexamethasone was not associated with decreased postoperative complications across all pancreatoduodenectomy patients. However, within the PDAC subgroup, there were fewer Clavien-Dindo ⩾ 3 complications after dexamethasone compared to no glucocorticoid administration.
- by Lorenzo FalchiEpcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved as monotherapy for relapsed/refractory (R/R) follicular lymphoma (FL). We evaluated fixed-duration epcoritamab with rituximab plus lenalidomide (R2) in R/R FL in arm 2 of EPCORE® NHL-2 (phase 1b/2; NCT04663347). Patients received epcoritamab (2 step-up doses, then 48-mg full doses) for up to 2 years and R2 for […]
- by Antti S RannikkoNo abstract
- by Sini VahteraCONCLUSIONS: A low hepsin expression following neoadjuvant therapy is associated with a better treatment response among those receiving gemcitabine-based treatment. Thus, hepsin does not appear to influence prognosis in pancreatic cancer patients, regardless of whether they received neoadjuvant therapy or not.
- by Meng LanCONCLUSION: Trop2-BA-ss-PPEP was successfully constructed. The targeting ability, microenvironment responsiveness, and anti-tumor metastatic effects of Trop2-BA-ss-PPEP provide a new strategy for TNBC therapy, which has good application and transformation potential.
- by Brittany L FordWilms tumor 1 (WT1) is a tumor-associated antigen expressed in solid tumors and hematological malignancies. T-cell immunotherapies targeting WT1 are currently under development. To analyze endogenous T-cell responses against WT1, we trained computational models capable of detecting WT1-specific T-cell responses from T-cell receptor (TCR) sequencing data. We peptide-pulsed healthy donor and acute myeloid leukemia (AML) […]
- by Fengjie LiuThe inflammatory microenvironment (IME) is closely related to the progression of triple-negative breast cancer (TNBC). As an anti-inflammatory active compound, poor solubility and targeting limit the potential of baicalin (BA) to modulate IME in TNBC. In this study, BA loaded bifunctional albumin nanoparticles (BANP) with long circulation/acid-sensitive release and active targeting functions are developed to […]
- by Fabien BertillotIntratumoral heterogeneity, originating from genetic, epigenetic, and phenotypic cellular diversity, is pervasive in cancer. As these heterogeneous states employ diverse mechanisms to promote tumor progression, metastasis, and therapy resistance, emergence of cancer heterogeneity is one of the most significant barriers to curative treatment. Here we leverage deep learning approaches to develop a high-throughput image-analysis paradigm […]
- by Fansu MengBreast cancer (BC) stands as one of the primary malignancies threatening women's health. Baicalin (BA) exhibits anti – BC effects, yet it is plagued by issues such as low water solubility and poor bioavailability. To enhance the anti-BC efficacy of BA, this study developed a pH – responsive albumin nanoparticle loaded with BA (BA-AN-FA@mPEG). The […]